* 3-Dimensional Pharmaceuticals Inc., of Exton, Pa.,received a three-year, $2 million Advanced TechnologyProgram award from the U.S. Department of Commercefor research into the three dimensional structures of G-protein coupled receptors. The company said defining thestructure of the receptors may have implications for drugsto treat cancer, pain, schizophrenia as well as cardiac andmetabolic disorders.
* Applied Immune Sciences Inc. and Japanese-basedAsahi Medical Co. began a pivotal clinical study in Japanwith Applied Immune's AIS CELLector CD5/CD8 forbone marrow transplants.
* Germany-based Boehringer Mannheim GmbH, asubsidiary of Corange Ltd., of Bermuda, has agreed topay $5 million to the Joslin Diabetes Center, of Boston,for research into diabetes.
* Cytel Corp., of San Diego, acquired ReceptorLaboratories Inc., of Charlottesville, Va., for $1.8 millionworth of Cytel stock. In addition, Receptor shareholdersagreed to invest $1.5 million in Cytel to supportcontinuation of the Charlottesville operation. Receptorhas technology for identification of antigenic peptidesthat stimulate immune system production of cytotoxic Tlymphocytes.
* EnzyMed Inc., of Iowa City, which uses enzyme-basedcombinatorial chemistry to create libraries of organicmolecules, entered a research collaboration with DuPontAgricultural Products, a subsidiary of the Wilmington,Del.-based E.I. Du Pont & Co.. Terms were not disclosed.
* GenPharm International Inc., of Mountain View, Calif.,sold its transgenic laboratory products division to TaconicFarms Inc., of Germantown, N.Y. Terms were notdisclosed. The sale includes eight GenPharm transgenicanimal models, such as the TSG-p53 transgenic mouse,which is deficient in the p53 tumor suppressor gene.
* Interneuron Pharmaceuticals Inc., of Lexington, Mass.,said a double-blind, placebo-controlled study in the U.K.of melatonin showed low doses of the drug helpedovercome insomnia and improved subjects quality ofsleep. Melatonin is a hormone secreted by the pinealgland in the brain and is involved in regulating sleepingand walking.
* Progenitor Inc., of Columbus, Ohio, licensed fromVanderbilt University in Nashville, Tenn., a patent for thedevelopmental endothelial locus-1 gene, which expressesa protein thought to be involved in the growth ofendothelial cells and blood vessels. Vanderbilt willreceive royalties on any products. Progenitor is asubsidiary of Interneuron Pharmaceuticals Inc., ofLexington, Mass.
* Protein Design Labs Inc., of Mountain View, Calif.,began a Phase II trials of its monoclonal antibody fortreatment of cytomegalovirus (CMV) retinitis in AIDSpatients. The studies of the human anti-CMV antibodyare being conducted in association with the NationalInstitute of Allergy and Infectious Diseases. In addition,Johns Hopkins University and the National Eye Institutewill conduct a separate Phase II/III trial with themonoclonal antibody for CMV in AIDS patients.
* Sepracor Inc., of Marlborough, Mass., said OFDPartners L.P., of New York, exercised warrants topurchase 793,650 Sepracor shares for $5 million.
* The Immune Response Corp., of Carlsbad, Calif.,received FDA clearance to test its psoriasis therapy in aPhase II trial.
(c) 1997 American Health Consultants. All rights reserved.